Oncology Corporate Profile
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding __´1.2 billion in 2013. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins.
|Somatuline® Depot||lanreotide||Somatuline® Depot is a somatostatin analog indicated for:|
-the long-term treatment of acromegalic patients who have had an
inadequate response to or cannot be treated with surgery and/or radiotherapy.
-the treatment of adult patients with unresectable, well- or moderatelydifferentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
-the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analogue rescue therapy.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|somatuline||somatostatin analog inhibitor||Neuroendocrine tumor||III|
|decapeptyl (triptorelin pamoate)||decapeptide analogue||Prostate cancer||III|
|tasquinimod||oral quinolone-3-carboxamid||Prostate cancer||II||Active Biotech|
|tasquinimod||oral quinolone-3-carboxamid||Various cancer types||II|
View additional information on product candidates here »